Lipocine Advances Phase 3 Postpartum Depression Drug Trial

The latest announcement is out from Lipocine ( (LPCN) ).

On January 12, 2026, Lipocine reported that an independent Data Safety Monitoring Board completed its second planned interim safety review of the company’s Phase 3 trial of LPCN 1154, an oral brexanolone candidate for rapid treatment of postpartum depression, and recommended the study continue without modification. The review, based on safety data from 82 randomized participants, found no drug-related serious adverse events, no excessive sedation, no loss of consciousness, and no treatment discontinuations, with only one dose reduction due to an adverse event, and the trial has stopped screening new participants while continuing to enroll eligible women in an outpatient setting without required medical monitoring. The company said it remains on track to report topline safety and efficacy data early in the second quarter of 2026, with the Phase 3 results expected to support a 505(b)(2) new drug application later that year, underscoring LPCN 1154’s potential to become a first-line, convenient at-home therapy that could shift the treatment paradigm in postpartum depression if ultimately approved.

The most recent analyst rating on (LPCN) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Lipocine stock, see the LPCN Stock Forecast page.

Spark’s Take on LPCN Stock

According to Spark, TipRanks’ AI Analyst, LPCN is a Neutral.

The score is held down primarily by weak financial performance (losses and persistent cash burn) and limited valuation support (negative P/E and no dividend). Strong technical momentum and an uptrend above major moving averages provide the main offset, though overbought indicators add near-term risk.

To see Spark’s full report on LPCN stock, click here.

More about Lipocine

Lipocine Inc. is a Salt Lake City-based biopharmaceutical company that leverages a proprietary technology platform to develop innovative orally delivered therapeutics targeting large addressable markets with significant unmet medical needs. Its pipeline includes candidates for postpartum depression, major depressive disorder, treatment-resistant depression, epilepsy, essential tremor, obesity management, liver cirrhosis symptoms, and prevention of preterm birth, alongside an FDA-approved oral testosterone product for male hypogonadism.

Average Trading Volume: 84,913

Technical Sentiment Signal: Buy

Current Market Cap: $41.81M

See more insights into LPCN stock on TipRanks’ Stock Analysis page.